Serum Markers as a Predictor of Response Duration and Patient Survival After Hormonal Therapy for Metastatic Carcinoma of the Prostate
- 1 April 1997
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 157 (4) , 1329-1334
- https://doi.org/10.1016/s0022-5347(01)64963-2
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- How Much Can We Rely on the Level of Prostate-Specific Antigen as an End Point for Evaluation of Clinical Trials? A Word of Caution!JNCI Journal of the National Cancer Institute, 1996
- PROSTATIC ACID PHOSPHATASE IN 1993Urologic Clinics of North America, 1993
- Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III eortc trial (30853)Urology, 1993
- Audit and its Impact in the Management of Early Prostatic CancerBritish Journal of Urology, 1993
- Orchiectomy and Nilutamide or Placebo as Treatment of Metastatic Prostatic Cancer in a Multinational Double-Blind Randomized TrialJournal of Urology, 1993
- Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancerCancer, 1992
- The Clinical Usefulness of Serum Prostate Specific Antigen After Hormonal Therapy of Metastatic Prostate CancerJournal of Urology, 1992
- Prostate Specific Antigen: A Critical Assessment of the Most Useful Tumor Marker for Adenocarcinoma of the ProstateJournal of Urology, 1991
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- Chemotherapy of advanced prostatic cancer Evaluation of response parametersUrology, 1976